08.10.2015 Views

BULLETIN

CSQ-Bulletin93

CSQ-Bulletin93

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Page 17 | Bulletin 93 | September 2015<br />

www.niaa-hsrc.org.uk<br />

The 6th National Audit Project<br />

Perioperative Anaphylaxis<br />

Nigel Harper, MAHSC Honorary Clinical Professor of Anaesthesia and Perioperative Medicine, University of Manchester<br />

Tim Cook, Consultant in Anaesthesia and Intensive Care Medicine, Royal United Hospital Bath<br />

and Director of the National Audit Projects<br />

Perioperative Anaphylaxis was selected<br />

from a general call for submissions as<br />

the subject for the 6th National Audit<br />

Project (NAP) of the Royal College<br />

of Anaesthetists (RCoA) and, like<br />

previous NAPs, will involve every NHS<br />

hospital in the UK. This article is an<br />

introduction to the latest NAP.<br />

Why?<br />

Perioperative anaphylaxis is a rare lifethreatening<br />

event that is unexpected<br />

and unannounced, requiring immediate<br />

and skillful management followed by<br />

expert investigation. Anaphylaxis may<br />

not be the first diagnosis that comes to<br />

mind; there are much more common<br />

causes of perioperative hypotension<br />

and bronchospasm, for example.<br />

An individual anaesthetist may<br />

encounter only a handful of cases<br />

during their career, although many<br />

colleagues may consider they have<br />

already seen more than their quota.<br />

Important questions abound. What<br />

is the UK incidence of perioperative<br />

anaphylaxis? How many patients<br />

experience cardiac arrest as a result<br />

of perioperative anaphylaxis? What<br />

is the burden on intensive care<br />

services? What are the outcomes of<br />

perioperative anaphylaxis and what<br />

are the factors associated with poor<br />

outcome? Are some drugs more likely<br />

to cause anaphylaxis than others?<br />

Is perioperative anaphylaxis to<br />

chlorhexidine on the increase? Is latex<br />

allergy no longer a significant problem?<br />

Is there an epidemic of anaphylaxis<br />

to blue dye during breast surgery?<br />

How common and how severe is nonallergic<br />

perioperative anaphylaxis? Is<br />

the problem less or more frequent in<br />

children? Are some patients more prone<br />

to develop perioperative anaphylaxis<br />

than others? How many patients<br />

experience cardiac arrest as a result<br />

of perioperative anaphylaxis? What<br />

proportion of cases are reported to the<br />

Medicines and Healthcare products<br />

Regulatory Agency (MHRA) through the<br />

yellow-card system?<br />

Then there are questions relating<br />

to the immediate management<br />

of perioperative anaphylaxis. Is<br />

adrenaline really necessary in every<br />

patient? How much variation is there<br />

in the dose of adrenaline required?<br />

How often is it necessary to administer<br />

an infusion of adrenaline? How<br />

often is noradrenaline, vasopressin,<br />

glucagon or sugammadex used to<br />

treat perioperative anaphylaxis? How<br />

much intravenous fluid is actually<br />

administered during resuscitation?<br />

We have partial answers to a few of<br />

these many questions, but only a large<br />

UK-wide audit can offer the prospect<br />

of more complete knowledge and<br />

consequent patient benefit.<br />

Referring a patient for further<br />

investigation of suspected perioperative<br />

anaphylaxis should be straightforward,<br />

but how established are the referral<br />

routes from anaesthetist to allergy<br />

clinic? How many such specialist clinics<br />

exist in the UK? Is there geographical<br />

variation in specialist allergy clinic<br />

provision? Do the clinics provide a<br />

good service and do they make helpful<br />

recommendations to patients and<br />

anaesthetists? NAP6 also seeks to<br />

answer some of these questions and<br />

to point the way to potential service<br />

improvement with the collaboration of<br />

allergy professionals and patient groups.<br />

What and when?<br />

NAP6 is being conducted by the RCoA<br />

through the Health Services Research<br />

Centre (HSRC). The steering panel<br />

was convened in March 2015 and<br />

includes representation from the<br />

Association of Anaesthetists of Great<br />

Britain & Ireland, the Association<br />

of Paediatric Anaesthetists of Great<br />

Britain & Ireland, the Association for<br />

Perioperative Practice, the Faculty of<br />

Intensive Care Medicine, the HSRC,<br />

the MHRA, the Obstetric Anaesthetists’<br />

Association, the Research & Audit<br />

Federation of Trainees, the Royal<br />

Pharmaceutical Society and the Safe<br />

Anaesthesia Liaison Group, and also<br />

professional allergy organisations and<br />

patient groups.<br />

NAP6 will seek reports of every case<br />

meeting the following criteria during<br />

the data collection period:<br />

■■<br />

Grade 3, 4 and 5 reactions (i.e. –<br />

severe reactions, life-threatening<br />

reactions and deaths). Minor<br />

reactions such as localized rash<br />

or anticipated hypotension or<br />

bronchospasm will be excluded).

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!